Enanta Pharmaceuticals, which is currently using its proprietary Peptide Morphing technology to identify new small-molecule drug candidates in the anti-infective category, has raised a second venture funding round totalling $20 million.
Oxford Bioscience Partners led the round, which also included Advent International, Caduceus Capital. Bank Vontobel. Alpinvest International, KB Luc Venture Capital and TVM Techno Venture Management. TVM was an existing shareholder in the firm, having led a $5.1 million syndicated equity round for Enanta last year.
Enanta, whose core technology is licensed exclusively from Harvard University, intends to take its drug compounds through Phase I and II clinical trials before out-licensing them to pharmaceutical partners.